Optimizing Lead Therapeutic Compounds Against Infectious Diseases

优化针对传染病的先导治疗化合物

• 批准号: 9332178
• 负责人: EVA GARLAND
• 金额: $ 27.3万
• 依托单位: AGILE SCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-30 至 2017-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9332178
• 关键词: Antimicrobial Resistance; Clinical; Communicable Diseases; Development; Future; Gram-Negative Bacteria; Gram-Positive Bacteria; In Vitro; Lead; Pharmaceutical Chemistry; Series; Staging; Testing; Therapeutic; Toxic effect; bacterial resistance; drug candidate; in vivo; infectious disease treatment; novel; pre-clinical; small molecule; therapeutic development

To support the advancement of promising lead therapeutics to the clinical drug candidate stage for the treatment of infectious diseases. Activities that may be supported include medicinal chemistry and preclinical in vitro and in vivo testing of a lead compound series in order to produce profiles of their efficacy, synthetic feasibility, stability, and toxicity, which will be used to identify a novel small molecule drug candidate for future clinical development.

支持将前景看好的先导疗法推进到治疗传染病的临床候选药物阶段。可能得到支持的活动包括药物化学和先导化合物系列的临床前体外和体内测试，以产生其有效性、合成可行性、稳定性和毒性的概况，这些将用于为未来的临床开发确定一种新的小分子候选药物。